Recurrent Multiple Myeloma


Darzalex® Approved for Additional Indications in Multiple Myeloma (November 29, 2016)

The United States Food and Drug Administration (FDA) has approved Darzalex® (daratumumab) for the treatment of multiple myeloma among patients who have received at least one prior therapy. The new FDA... Continue Reading

Darzalex™ Effective in Heavily Pre-Treated Multiple Myeloma (July 7, 2016)

The targeted agent Darzalex (daratumumab) produces long-lasting anti-cancer responses among patients with multiple myeloma that has stopped responding to several prior therapies. These results were recently... Continue Reading

News Briefing in St. Louis on May 24 Addressing the Impact of ICER’S “Value” Determinations for New Multiple Myeloma Therapies (May 24, 2016)

News Conference Will Be Live Streamed RIGHT HERE at: 11 AM EDT; 10 AM CDT To Register Your Attendance: CLICK HERE In advance of the Institute for Clinical and Economic Research’s (ICER) plan to debate... Continue Reading

Ask the Expert: Multiple Myeloma (May 4, 2016)

CancerConnect recently collaborated with The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute (OSUCCC – James) to provide you with the opportunity... Continue Reading

Have a Question about Multiple Myeloma? Join us on April 28th (April 26, 2016)

CancerConnect and The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute Will Present: Ask the Expert with Dr. Hofmeister CancerConnect in collaboration... Continue Reading

Aplidin® Improves Progression-Free Survival in Multiple Myeloma (April 21, 2016)

The addition of the investigative agent Aplidin® (plitidepsin) to dexamethasone appears to significantly reduce the risk of cancer progression or death compared to dexamethasone alone among patients with... Continue Reading

Combo Therapy of Kyprolis plus Dexamethasone Approved for Recurrent Multiple Myeloma (January 26, 2016)

The United States Food and Drug Administration (FDA) recently approved a new treatment combination consisting of Kyprolis (carfilzomib) plus dexamethasone for patients with relapsed or refractory multiple... Continue Reading

Leukemia and Lymphoma Society Summarizes Major Advances in Treatment of Blood Cancers Presented at American Society of Hematology Meetings (December 31, 2015)

For the more than one million Americans living with or in remission from a blood cancer, there is more hope than ever for new treatments and even cures—not someday, but today. Clinical findings presented... Continue Reading

FDA Approves Empliciti for Multiple Myeloma (December 7, 2015)

The United States Food and Drug Administration (FDA) has approved Empliciti (elotuzumab) for the treatment of patients with multiple myeloma who have received prior therapies. The indication specifies... Continue Reading

Ninlaro® Approved for Multiple Myeloma (November 23, 2015)

The United States Food and Drug Administration (FDA) has granted approval to Ninlaro® (ixazomib) for the treatment of multiple myeloma. This marks the third drug approved this year for the treatment of... Continue Reading

FDA Approves Darzalex Providing a New Treatment for Patients with Multiple Myeloma (November 17, 2015)

Today the U.S. Food and Drug Administration granted accelerated approval for Darzalex (daratumumab) to treat patients with multiple myeloma. Darzalex is the first monoclonal antibody approved for treating... Continue Reading

Ask the Expert: Blood Cancer Treatment Progress & What’s Next (October 7, 2015)

CancerConnect Presents: Ask the Expert: Blood Cancer Treatment Progress & What’s Next In this informative web chat, Jacqueline Barrientos, MD discusses blood cancer prevalence, evolution of blood... Continue Reading

Daratumumab Effective in Multiple Myeloma (September 17, 2015)

The targeted agent, daratumumab, which is still in clinical trials, appears to be effective in patients with multiple myeloma that has stopped responding to standard therapies. These results were recently... Continue Reading

Immunotherapy Benefits Patients with Drug-Resistant Multiple Myeloma (September 2, 2015)

In its first clinical trial, a breakthrough antibody therapy produced at least partial remissions in a third of patients with multiple myeloma who had exhausted multiple prior treatments, investigators... Continue Reading

Investigational T-cell Receptor Therapy Achieves Encouraging Clinical Responses in Multiple Myeloma Patients, Penn-led Study Finds (July 22, 2015)

Results from a clinical trial investigating a new T cell receptor (TCR) therapy that uses a person’s own immune system to recognize and destroy cancer cells demonstrated a clinical response in 80 percent... Continue Reading

National Multiple Myeloma Awareness Month on CancerConnect (March 3, 2015)

Sun Valley, ID & Fort Worth, TX– OMNI Health Media (OMNI) announces the launch of multiple myeloma educational programs for national multiple myeloma awareness month. As the month of March brings... Continue Reading

Farydak® Approval Provides Another Treatment Option for Patients With Multiple Myeloma (February 25, 2015)

Novartis announced today that the US Food and Drug Administration (FDA) has approved Farydak® (panobinostat) in combination with Velcade® and dexamethasone for the treatment of patients with multiple... Continue Reading

Further Findings Show Pomalyst plus Low-Dose Dexamethasone Safe and Effective in Relapsed or Refractory Multiple Myeloma (January 26, 2015)

For patients with relapsed or refractory multiple myeloma, treatment with Pomalyst® (pomalidomide) plus low-dose dexamethasone appears safe and effective. These findings were presented at the 56th American... Continue Reading

Next Page »

Sign up for the CancerConnect newsletter

Sign up for our newsletter and receive the latest news and updates about specific types of cancer.

  Close |  Please don't show me this again

Facebook Twitter RSS